Lisdexamfetamine Dimesylate Capsule Shortage: FDA Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has reported a current shortage of Lisdexamfetamine Dimesylate Capsules due to a shortage of an active ingredient, affecting some manufacturers while others remain available.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Lisdexamfetamine Dimesylate.
What's in Shortage
The generic drug name is Lisdexamfetamine Dimesylate Capsule. Brand names include LISDEXAMFETAMINE DIMESYLATE. The dosage form is Capsule. The current status is a shortage, initially posted on 07/14/2023 and last updated on 04/01/2026. This medication falls under the therapeutic category of Psychiatry.
Which Manufacturers Are Affected
Several manufacturers are involved, with varying availability:
- Elite Laboratories, Inc.: Limited Availability for presentations including 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg Capsules; estimated recovery: TBD; contact: 888-852-6657.
- Mylan Pharmaceuticals Inc., a Viatris Company: Available for 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg Capsules; contact: 800-796-9526.
- Apotex Corp.: Available for 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg Capsules; contact: 800-706-5575.
- Lannett Company, Inc.: Available for 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg Capsules; contact: 844-834-0530.
- Teva Pharmaceuticals USA, Inc.: Available for most presentations including 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg Capsules, but Limited Availability for 70 mg Capsule with estimated recovery: May 2026; contact: 800-545-8800.
- Alvogen: Available for 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg Capsules; contact: 844-842-8672 and email: CustomerService-US@alvogen.com.
Why There's a Shortage
The shortage is due to a shortage of an active ingredient.
What Patients Should Do
If you rely on this medication, talk to your pharmacist about availability. You may also contact the manufacturer directly using the provided contact information to inquire about supply. Remember, patients should consult their healthcare provider for any concerns or guidance related to their treatment.
Source
This information is from the FDA Drug Shortage Database, with the shortage initially posted on 07/14/2023 and last updated on 04/01/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,951 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.